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Abstract
The accumulation of irreversible advanced glycation endproducts (AGEs) on long-lived proteins, and the interaction of AGEs
with cellular receptors such as AGE-R3/galectin-3 and RAGE, are considered to be key events in the development of long-
term complications of diabetes mellitus, Alzheimer’s disease, uremia and ageing. The aim of this study was to investigate
the expression and sub-cellular distribution of galectin-3, as well as its possible modulation by AGEs, in MC3T3E1 mouse
calvaria-derived osteoblasts and in UMR 106 rat osteosarcoma cells. Both osteoblastic lines were cultured either with control
bovine serum albumin (BSA) or with AGEs-BSA for 48 h. Cells were evaluated for galectin-3 expression by fixing and
immunofluorescent microscopic analysis; or Western blot analysis of whole cell extracts, sub-cellular fractions and culture
media. Both cell lines express 30 kDa (monomeric) galectin-3, although expression was about 15-fold lower in the UMR106
osteosarcoma cells. Dimeric (70 kDa) galectin-3 was additionally observed in the UMR106 cells. Immunofluorescent analysis
of galectin-3 distribution showed a diffuse cytoplasmic and strong nuclear pattern in MC3T3E1 osteoblasts, and a patchy
cytoplasmic pattern in UMR106 cells. Western blot analysis for both cell lines showed that galectin-3 was mainly found in
the cytoplasm and in minor amounts in the microsomal fraction, while considerable amounts were secreted into the culture
media. Exposure to 100–200 µg/mL AGEs-BSA increased the cellular content of 30 kDa galectin-3 (20–25% for MC3T3E1
and 35–70% for UMR106 versus control BSA, p < 0.05), and decreased the culture media levels of galectin-3 (10–20% for
MC3T3E1 and for UMR106 versus control BSA, p < 0.05). These results confirm the expression of galectin-3 in osteoblastic
cells, and suggest different levels and sub-cellular distribution of this protein in transformed versus non-transformed osteoblasts.
Osteoblastic exposure to AGEs alters their expression and secretion of galectin-3, which could have significant consequences
on osteoblast metabolism and thus on bone turnover. (Mol Cell Biochem 266: 17–24, 2004)
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Introduction
Recent research indicates that an increase in the steady-state
levels of highly reactive dicarbonylic compounds (“carbony1
stress”) may lead to the formation of advanced glycation
endproducts (AGEs). AGE products could be involved in
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the etiology of the long-term complications of several hu-
man afflictions, such as diabetes mellitus, ageing, uremia
and Alzheimer’s disease [1, 2]. An increase in the gener-
ation of AGEs can be partly explained by the process of
non-enzymatic glycosylation of proteins. Cell surface recep-
tors for AGE moieties have been detected on different cell
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types. These proteins appear to contribute to diverse cellular
functions, such as the specific recognition and degradation
of AGE-modified proteins [3]. In fact, several AGE-binding
proteins have been identified, including the receptor com-
plex of oligosaccharyltransferase-48 (AGE-R1), an 80 kDa
protein homologous to the PKC substrate 80 K-H (AGE-R2)
and galectin-3, a 30 kDa protein (AGE-R3); RAGE, a 35 kDa
member of the immunoglobulin superfamily of receptors; and
macrophage scavenger receptors type I and type II.
We have previously demonstrated that soluble AGE-
modified proteins can regulate the growth of mouse
MC3T3E1 and rat UMR106 osteoblast-like cells: while ini-
tially eliciting an increase in cellular proliferation and differ-
entiation, a longer exposure to AGE-modified bovine serum
albumin (BSA) induces a significant decrease in both param-
eters [4]. We have also described the presence of membrane-
associated receptors in both cell lines, which specifically par-
ticipate in the recognition and degradation of AGE-modified
proteins. The expression of these receptors is differentially
regulated according to the osteoblastic development stage
[5]. Radiolabelled ligand blotting studies show the presence
of several binding proteins with apparent molecular masses
of 50, 45–40, 30, 25 and 18 kDa; the major bands corre-
sponding to 30 and 25 kDa proteins. These results suggest
that RAGE and AGE-R3 (galectin-3) are the principal AGE
receptor candidates in cultured osteoblast-like cells.
RAGE, one of the best-characterized AGE receptors, is
present in endothelial cells, vascular smooth muscle cells,
cardiac myocytes, monocytes, microglia and neurons [6]. We
have recently shown that RAGE is expressed in osteoblas-
tic cells, and that exposure to AGEs increases the cellular
levels of RAGE in a manner that depends on the stage of
osteoblastic development [7]. These changes in RAGE ex-
pression were closely followed by activation of extracellu-
lar signal regulated kinases (ERK-1/2). The observed results
led us to suggest that a pathological accumulation of AGEs
in bone extracellular matrix, its recognition by osteoblastic
RAGE and the consequent generation of signal transduction
pathways regulating ERK activation, could lastly affect bone
formation and/or remodeling.
Galectin-3 is a member of a family of lactose/galactose-
specific lectins [8, 9]. Galectin-3 interacts with the β-
galactoside residues of several extracellular matrix proteins
(ECM) and cell surface glycoproteins through the C-terminal
carbohydrate recognition domain (CRD). Additional interac-
tion with proteins and nucleic acids have been described as
mediated by the N-terminal domain [9, 10]. Galectin-3 is
present in various cell types, including those of the myeloid
lineage, osteoblasts, chondrocytes, neurons and glial cells;
epithelia are major sites of galectin-3 expression. Galectin-3
shows a ubiquitous localization within the cells: although it
is localized mainly in the cytoplasm, it is also translocated
into the nucleus and released to the extracellular space [8].
AGE-BSA may be a glycoconjugated mimic of physiological
ligands of galectin-3. The AGE-BSA binding to galectin-3 is
not inhibited by lactose, suggesting that a different domain
than CRD is involved in this interaction [10]. The capacity of
galectin-3 to bind AGEs has been demonstrated in different
cell types such as macrophages, human astrocytes, human
umbilical vein endothelial cells, mesangial cells and mouse
liver sinusoidal endothelial cells.
The accumulation of AGEs on bone proteins may play a
role in the pathogenesis of the osteopenia present in poorly
controlled diabetic patients [11]. This osteopenia has been
attributed to long-term decrease in the recruitment and bone-
forming activity of osteoblasts [12], which could in turn be
due to a pathological increase in the interaction between ex-
tracellular matrix AGEs and specific receptors such as RAGE
and galectin-3.
In this study we investigated the expression and distribu-
tion of galectin-3 in two osteoblast-like cells in culture, and
the effect(s) of exposure to AGEs. Results indicate that the
expression, subcellular distribution, and secretion of galectin-
3 is different in transformed versus non-transformed os-
teoblasts. Further, their exposure to AGEs increased galectin-
3 expression and reduced secretion, suggesting a significant
role of AGEs in modulation of osteoblast metabolism and
bone turnover.
Materials and methods
Materials
BSA, ribose, Triton X-100, prestained molecular weight
standards, Kodak XAR-5 photographic films, 5-amino-2,3-
dihydro-1,4-phthalazine dione (luminol), and p-coumaric
acid, goat anti-rabbit IgG-FITC were from Sigma (St. Louis,
MO, USA). Centricon 10 kDa cut-off filter cartridges were
from Amicon Inc. (Beverly, MA, USA). Dulbecco’s modified
Eagle’s medium (DMEM), trypsin-EDTA and fetal bovine
serum (FBS) were from Gibco, (Life Technology, Buenos
Aires, Argentina) and tissue culture disposable material was
from Nunc (Buenos Aires, Argentina). Rabbit polyclonal
anti-galectin-3 (directed against C-terminal CRD) antibody
was a gift from J.L. Wang, Michigan State University, East
Lansing, MI, USA. Vectashield-DAPI mounting media was
from Vector Laboratories, Inc. (Burlingame, CA, USA).
Preparation of AGEs
AGE-BSA was produced by incubation of 10 mg/ml BSA
with 100 mM ribose in 150 mM phosphate-buffered saline
(PBS), pH 7.4 at 37 ◦C for 6 weeks [4]. Ribose was used as
glycating sugar instead of glucose to speed up non-enzymatic
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glycosylation. Control BSA was incubated in the same
conditions without sugar. Unbound sugar was removed by
centrifugation/filtration with centricon filter cartridges. The
formation of AGEs was assessed by their characteristic
fluorescence-emission maximum at 420 nm upon excita-
tion at 340 nm [4]. The estimated levels of AGE-BSA ob-
tained in this in vitro incubation was 18.5% relative flu-
orescence intensity/mg protein, as opposed to 3.2% for
control-BSA.
Cell culture and incubation
UMR106 rat osteosarcoma cells and MC3T3E1 mouse
calvaria-derived cells were grown in DMEM containing
10% FBS, 100 U/ml penicillin and 100 µg/ml strepto-
mycin. Cells were seeded on 75 cm2 flasks and sub-
cultured using trypsin-EDTA and replated on 35 mm dishes.
To study the effect of AGEs, cells were incubated in a
serum-free DMEM in the presence of different concentra-
tions of AGE-BSA or control-BSA for the indicated pe-
riods of time. Conditioned media was saved, concentrated
by Amicon 10 kDa cartridges, lyophilized and stored at
−20 ◦C. Cell monolayers were washed with cold PBS
and lysed in Laemmli’s buffer [14] and the protein con-
tent of the lysates evaluated [15]. The conditioned me-
dia and lysates were used for Western blot analysis of
galectin-3.
Preparation of whole cell homogenates and cell
fractionation
Cell monolayers were resuspended in 25 mM Tris, 250 mM
sucrose, 2 mM EDTA, 5 mM β-mercaptoethanol, 1 mM
PMSF, pH 7.4 and sonicated. Cell fractioning was carried out
by differential centrifugation as described elsewhere [16], the
protein concentration of the cell fractions assessed [15], and
stored at −20 ◦C until use.
Western analysis of galectin-3
The samples were heated at 100 ◦C for 3 min and the in-
dicated amount of protein subjected to 13.7% SDS-PAGE.
The separated proteins were then transferred to nitrocellu-
lose membranes. After washing and blocking, the membranes
were incubated with 1:1500 rabbit polyclonal anti-galectin-
3 antibody. Blots were developed using chemiluminiscence
reagents. The intensity of the specific bands was semi-
quantified by densitometry after scanning of the photo-
graphic film. Images were analysed using the public do-
main Scion Image-beta2 program (available from Internet
http://www.scioncorp.com).
Immunofluorescence microscopy
Sub-confluent osteoblasts grown on glass coverslips were
washed in PBS, fixed with 4% paraformaldehyde in
PBS (10 min at room temperature) and permeabilized with
ethanol for 4 min at −20 ◦C. Non-specific binding sites
were blocked with 10% normal goat serum in PBS for 2
h. Cells were then incubated with rabbit polyclonal anti-
galectin-3 antibody (1:100 in blocking buffer) overnight at
4 ◦C. After washing, cells were exposed to a goat anti-rabbit
IgG-FITC (1:200) for 2 h at room temperature. Cells were
mounted in vectashield-DAPI and observed in a fluorescence
microscope.
Statistical analysis
Three independent experiments were run for each experimen-
tal condition. Results are expressed as the mean ± S.E.M.
Statistical analysis of the data was performed by Student’s
t-test. Correlation among different parameters was analysed
using Pearson’s coefficient as well as the linear regression
method.
Results
Expression of AGE-R3/galectin-3 in osteoblast-like cells
Western blot analysis was performed on protein extracted
from two osteoblast-like cell lines after a 48-h culture in
DMEM, probed with an anti-galectin-3 antibody (Fig. 1).
The non-transformed MC3T3E1 osteoblastic line revealed
a major band of approximately 30 kDa cross-reactive with
galectin-3 (Fig. 1A). The UMR106 osteosarcoma line ex-
pressed cross-reactive components in the 30–35 kDa range,
although the intensity of the signal was weaker than in the
MC3T3E1 line (Fig. 1B). In addition, minor bands of 70–75
kDa were observed in the UMR106 cells, potentially repre-
senting dimeric galectin-3. By varying the sample size loaded
into the gels for Western blot analysis, it was estimated that
UMR106 cells contained approximately 15-fold less 30 kDa
galectin-3 than MC3T3E1 cells.
The subcellular distribution of galectin-3 in osteoblast-
like cells was investigated by assessing its presence in se-
lected cell fractions by Western blot. The protein was mainly
present in the cytoplasm, and in minor amounts in the micro-
somal fraction (Fig. 2A). In addition, considerable amounts
of galectin-3 were secreted into the DMEM 48 h-conditioned
culture media. We also examined the localization of galectin-
3 in intact cells by immunofluorescence microscopy. In the
MC3T3E1 cells, galectin-3 was associated with staining
of the cytoplasm and more intense staining of the nucleus
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Fig. 1. Correlation between galectin-3 expression and total cellular protein content in cultured osteoblasts. MC3T3E1 (A) and UMR106 (B) cells were cultured
until they reached confluence and cellular extracts were prepared in Laemmli’s buffer. Increasing concentrations of cellular protein, assessed by Lowry’s method,
were loaded on a 13.7% acrylamide gel. Galectin-3 was evaluated by Western immunoblot and developed by ECL. The corresponding 30 kDa galectin-3 bands
were quantitated by densitometry. Note the different scales used for cellular protein in panels A and B.
(Fig. 2B). Galectin-3 immunofluorescence in the UMR106
cells shows a more diffuse and punctate pattern, mainly as-
sociated with the cytoplasm (Fig. 2B).
Effect of AGEs on osteoblastic AGE-R3/galectin-3
expression
The effect(s) of AGEs on the expression of galectin-3 by
osteoblast-like cells was investigated by exposing MC3T3E1
and UMR106 cells in culture to increasing amounts of either
AGE-BSA or unmodified-BSA (control) for 48 h. Addition of
100 and 200 µg/ml AGE-BSA to the culture media resulted in
a statistically significant increase in galectin-3 expression in
both MC3T3El (Fig. 3A) and UMR106 (Fig. 3B) osteoblast-
like cells. Because galectin-3 is also released into the culture
media, we next investigated the effect of AGEs on the levels
of secreted galectin-3. Exposure to AGE-modified BSA re-
sulted in lower levels of galectin-3 in both in the MC3T3E1-
(Fig. 4A) and in the UMR106- (Fig. 4B) conditioned media.
Discussion
The deleterious effect of AGE-modified proteins on different
tissues is at present well documented, and it is believed to
play a role in the pathogenesis of several diseases. In par-
ticular, our group [17] and other investigators have demon-
strated that accumulation of AGEs in the extracellular matrix
proteins induces significant alterations in osteoblastic devel-
opment. AGEs can exert their cellular effects by interacting
with several cell surface receptors [3], although their precise
mechanisms of action are incompletely known.
In this study we describe the expression and distribution
of AGE-R3/galectin-3 as well as its modulation by AGEs in
two osteoblast-like cell lines. We have used AGE-modified
BSA, which is a model previously employed by us and other
authors in different cell culture systems [18, 19]. The level
of glycation which we induced “in vitro” on BSA, is similar
to the AGE-modification measured by fluorescence analysis
by other authors in diabetic rat bone collagen [20, 21].
Aubin et al. [22] first described the expression of galectin-
3 in osteoblastic cells. These authors showed that readily
detectable levels of galectin-3 mRNA and protein were ex-
pressed in cultures of rat calvaria-derived cells and in ROS
17/2.8 rat sarcoma cells, although galectin-3 mRNA was
virtually undetectable in UMR106.01 cells. The authors at-
tributed these differences to the diverse stages of osteoblas-
tic cell maturation observed in each cell line. In the present
study, different expression and distribution patterns were
found for the non-transformed MC3T3E1 cell line and for
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Fig. 2. Subcellular/extracellular distribution of galectin-3. (A) Western blot
of galectin-3. Conditioned media were saved and the cell monolayers were
resuspended in a homogenization buffer and sonicated. Cell fractions were
prepared by successive centrifugations as described in Materials and meth-
ods. Protein concentration was assessed by the method of Lowry. M: mem-
brane fraction; C: cytosolic fraction; CE: cell extract; CM: conditioned me-
dia. (B) Immunofluorescence studies of galectin-3 in osteoblasts. Cells were
fixed, and incubated with anti-galectin-3 antibody and a FITC-conjugated
second antibody. Magnification: objective 100×.
the osteosarcoma-derived UMR106 cells. Other investiga-
tors have demonstrated that after a short period of culture
(24–72 h), the MC3T3E1 pre-osteoblastic cell line prolif-
erates and secretes type-I collagen, but expresses very low
levels of other osteoblastic markers such as alkaline phos-
phatase, osteocalcin and osteopontin [23]. In our present ex-
periments, after a 48-h culture, this cell line expressed high
levels of 30 kDa galectin-3 corresponding to a monomeric
form of the protein. On the other hand, the osteosarcoma
UMR106 osteoblast-like cells proliferate faster than the
MC3T3E1 cells, and have been found to express several early
osteoblastic markers such as type-I collagen secretion, high
levels of alkaline phosphatase, PTH receptors and a PTH-
dependent cAMP increment [24]. In the present study, when
it was protein-normalized, galectin-3 expression was found
to be 15-fold lower in the osteosarcoma line than in the
non-transformed MC3T3E1 line. In addition, several bands
that cross-react with the anti-galectin-3 antibody were de-
tected in the osteosarcoma cells, probably corresponding to
the monomeric and dimeric forms of this protein. This si-
multaneous presence of monomers and dimers of galectin-3
in UMR106 cells could be related to the patchy distribution
of galectin-3 by immunofluorescence which we have also
found in the present study, and might be indicating intra-
cellular dimerization and/or multimerization of the protein
Fig. 3. Regulation of galectin-3 expression by AGEs in MC3T3E1 (A) and
UMR106 (B) cells. Cells were cultured in serum-free DMEM in the presence
of AGE-BSA or control BSA during 48 h. Cellular extracts were prepared in
Laemmli’s buffer and galectin-3 was determined by Western immunoblot.
30 kDa bands were quantitated by densitometry. Differences versus control
are: ∗ p < 0.05.
in osteosarcoma cells. In comparison, in non-transformed
MC3T3E1 cells we found the intracellular galectin-3 im-
munofluorescent staining to be stronger and mainly concen-
trated in the nucleus, a pattern of galectin-3 distribution which
other authors have described to be typical of young cells in
active proliferation [25]. On the other hand, recent studies
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Fig. 4. Galectin-3 secretion to conditioned media from MC3T3E1 (A) and
UMR106 (B) osteoblastic cells. Cells were incubated in a serum-free DMEM
in the presence of different concentrations of AGE-BSA or control BSA for
48 h. Conditioned media were saved, concentrated by 10 kDa filter cartridges,
lyophilized and stored at −20 ◦C. Lyophilized media were resuspended in
Laemmli’s buffer and galectin-3 was analyzed by Western immunoblot. The
corresponding 30 kDa galectin-3 bands were quantitated by densitometry.
CE MC: MC3T3E1 30 kDa cell extract.
have shown that cytoplasmic, but not nuclear, distribution of
galectin-3 (such as we have found in the UMR106 osteosar-
coma cell line), is associated with progression of certain tu-
mors [26, 27].
Although the precise physiological roles of galectin-3 have
not been elucidated, it has been suggested that extracellu-
lar and membrane-associated galectin-3 could mediate cell
migration, cell adhesion and cell–cell interaction. In addi-
tion, nuclear galectin-3 seems to be involved in pre-mRNA
splicing, and anti-apoptotic actions of galectin-3 have also
been suggested [9]. Galectin-3 has the ability to dimerize or
multimerize and become associated with cellular proteins,
such as has recently been shown with synnexin, a Ca2+−
and phospholipid-binding protein that mediates the transport
of galectin-3 to the mitochondrial membrane [28]. Recently
Stock et al. [29] have shown that the expression of galectin-3
in skeletal tissue is controlled by Runx2, a transcription fac-
tor of the Runt family which is a key regulator of osteoblas-
tic development. The role of galectin-3 in the physiology of
osteoblastic development is not known; however, this pro-
tein could modulate several osteoblastic processes, includ-
ing proliferation, differentiation, mineralization and apopto-
sis. The role of galectin-3 as a receptor for AGEs was first
demonstrated in macrophages by binding experiments [11].
It has also been shown that AGEs can up-regulate galectin-3
expression in glomerular mesangial cells, suggesting a role
for this protein in tissue remodeling [30]. In our present study
with osteoblastic cells, we have found that AGE-BSA in-
creases the levels of cell-associated galectin-3, but decreases
the concentration of this protein in the culture media. This
increase in the osteoblastic content of galectin-3 could be due
either to an increase in its expression, or to a decrease in its
secretion. On the other hand, the observed AGEs-induced re-
duction in the galectin-3 content of the culture media could
be a consequence either of reduced osteoblastic secretion,
or of increased degradation of galectin-3 by extracellular
proteases. The same AGEs-induced redistribution pattern of
cellular/extracellular galectin-3 was found to occur both in
non-transformed and in osteosarcoma-derived cell lines. In
addition, the same doses of AGE-BSA and incubation time,
which induce the redistribution of galectin-3 described in the
present work, have been previously described by us to signifi-
cantly increase cell proliferation in both osteoblastic lines [4].
We have recently demonstrated the expression and AGEs-
dependent regulation of RAGE in osteoblasts [7]. In those
experiments it was noted that although a 24–72 h exposure to
AGEs did not modify the expression of RAGE in proliferat-
ing MC3T3E1 pre-osteoblasts, a similar exposure to AGEs of
UMR106 osteosarcoma cells significantly increased RAGE
protein expression. Those results suggested that receptors for
AGEs other than RAGE could be partly responsible for the
AGE-induced alterations in osteoblast-like cells. Our present
observations support this hypothesis and point to a role for
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galectin-3 in the effects of AGEs on bone development. The
accumulation of AGEs on bone proteins, as has been de-
scribed for type-I collagen obtained from diabetic and age-
ing rats [20, 21], could increase the occupancy and induce an
up-regulation of AGE-R3/galectin-3 and RAGE receptors,
both of which are expressed by osteoblastic cells. In addi-
tion, galectin-3 that is secreted into the extracellular space
in bone tissue may modulate cell–cell and cell–matrix inter-
actions, and probably contributes to the normal regulation of
bone turnover. Thus, an AGEs-induced alteration in the levels
of secreted galectin-3 could further contribute to steoblastic
(and bone) dysfunction. The discovery of the precise molec-
ular pathways that are triggered by the interaction between
AGEs and AGE-R3/galectin-3, will lead to the development
of more specific strategies for the control of AGE-induced
tissue alterations.
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